Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100696 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT02100696 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 609 participants.
The verdict
NCT02100696, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with moderately to severely active ulcerative colitis (UC) who have been previously exposed to TNF inhibitors.
Interventions
- DRUG Placebo
- DRUG Etrozulimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2014-05-21 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100696
The ClinicalTrials.gov registry entry for NCT02100696 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02100696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100696 about?
NCT02100696 is a clinical study titled "A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors". This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with moderately to severely active ulcerative colitis (UC) who have been pr...
What is the current status of trial NCT02100696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2014-05-21. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT02100696?
The interventions under investigation include: Placebo (DRUG), Etrozulimab (DRUG).
Who is sponsoring clinical trial NCT02100696?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.